These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8094822)

  • 1. Didanosine and ACTG 116A.
    Higgins S; Woolley PD; Chandiok S
    Lancet; 1993 Feb; 341(8844):570. PubMed ID: 8094822
    [No Abstract]   [Full Text] [Related]  

  • 2. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117.
    Richardson D; Liou SH; Kahn JO
    J Acquir Immune Defic Syndr (1988); 1993 Nov; 6(11):1212-23. PubMed ID: 8229656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
    Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
    Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued zidovudine or didanosine for human immunodeficiency virus infection.
    Behrman RE; Kammerman LA; Feigal DW
    N Engl J Med; 1992 Nov; 327(22):1598-9. PubMed ID: 1435893
    [No Abstract]   [Full Text] [Related]  

  • 7. Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
    Am J Health Syst Pharm; 1998 Jun; 55(11):1106, 1108. PubMed ID: 9626369
    [No Abstract]   [Full Text] [Related]  

  • 8. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    Clay PG; Rathbun RC; Slater LN
    JAMA; 1999 Jan; 281(2):130; author reply 131. PubMed ID: 9917107
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
    Khajotia RR; Feigley CE; Lee E; Gu J
    AIDS; 1998 Jan; 12(2):222-4. PubMed ID: 9468376
    [No Abstract]   [Full Text] [Related]  

  • 10. Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
    Haubrich R; Richman D
    JAMA; 1999 Jan; 281(2):130-1. PubMed ID: 9917108
    [No Abstract]   [Full Text] [Related]  

  • 11. Major pediatric study stopped early: combination treatment better.
    James JS
    AIDS Treat News; 1997 Jul; (No 274):5-6. PubMed ID: 11364462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
    Katzenstein DA; Hughes MD; Albrecht M; Liou SH; Murphy R; Balfour H; Para M; Hammer S;
    AIDS Res Hum Retroviruses; 2001 Feb; 17(3):203-10. PubMed ID: 11177402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
    Stamminger T; Fleckenstein B
    Fortschr Med; 1994 May; 112(13):190-1. PubMed ID: 8020860
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
    Foli A; Maserati R; Minoli L; Wainberg MA; Gallo RC; Lisziewicz J; Lori F
    AIDS; 1998 Jun; 12(9):1113-4. PubMed ID: 9662215
    [No Abstract]   [Full Text] [Related]  

  • 15. A bend in the road--implications of ACTG 175 and Delta trials.
    Hirsch MS; Yeni P
    Antivir Ther; 1996 Jan; 1(1):6-8. PubMed ID: 11322260
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
    Simonelli C; Zanussi S; Comar M; Vaccher E; Giacca M; De Paoli P; Tirelli U
    AIDS; 1998 Jan; 12(1):112-3. PubMed ID: 9456263
    [No Abstract]   [Full Text] [Related]  

  • 17. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for HIV infection.
    Med Lett Drugs Ther; 1990 Feb; 31(811):11-3. PubMed ID: 2153901
    [No Abstract]   [Full Text] [Related]  

  • 19. DDI more effective than AZT.
    Minn Med; 1992 Jun; 75(6):54. PubMed ID: 1495461
    [No Abstract]   [Full Text] [Related]  

  • 20. Didanosine (DDI) alone is now considered the first-line therapy for symptomatic children infected with the human immunodeficiency virus (HIV).
    J Am Osteopath Assoc; 1996 Jun; 96(6):339. PubMed ID: 8690619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.